News & Events about Vigil Neuroscience Inc.
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc.(Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company will host an adult-onset ...
Vigil Neuroscience (NASDAQ:VIGL Get Rating) had its price target hoisted by Morgan Stanley from $11.00 to $12.00 in a report published on Monday morning, MarketBeat reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also issued reports about the stock. ...
Ticker Report
2 months ago
Vigil Neuroscience (NASDAQ:VIGL Get Rating) had its price target hoisted by Morgan Stanley from $11.00 to $12.00 in a report published on Monday morning, MarketBeat reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also issued reports about the...
Globe Newswire
6 months ago
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc.(Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that it has entered into a securities purchase agreement ...
Globe Newswire
10 months ago
- Completed successful initial public offering, raising $98 million in gross proceeds - - Initiated VGL101 Phase 1 trial; Phase 2 trial in ALSP patients expected to initiate in 2H 2022 - - Initiated IND-enabling studies in the small molecule Alzheimers disease TREM2 agonist program - - Advanced ...